Curis cuts workforce ~30%, focuses on combo studies; cash runway into 2025

CURIS INC

Board approved ~30% workforce reduction as monotherapy trials near completion.
Company focusing on combination studies in CNS lymphoma and front-line AML.
Expects no significant 2024 cost impact; cost reductions anticipated in 2025.
Stockholders approved increasing authorized common shares to 34,171,875.
Stockholders approved additional 942,100 shares for 2010 Stock Incentive Plan.

item 3.03 item 5.03 item 5.02 item 5.07 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.